Skip to main content
. Author manuscript; available in PMC: 2013 Dec 30.
Published in final edited form as: Nature. 2012 Feb 8;482(7385):400–404. doi: 10.1038/nature10755

Figure 3. Identification of mutant spectrin-β2 as an authentic antigen of an unedited tumour.

Figure 3

a, b, IFN-γ release by C3 CTLs against different unedited sarcomas (a) or against d42m1-related tumours (b). c, IFN-γ release by C3 CTLs is inhibited by mAbs that block CD8 and H-2Db, but not CD4 or H-2Kb. d, MHC class I epitopes predicted to be shared in all of the regressor d42m1 tumours, but not in progressor d42m1 tumours. e, Representation of the cDNA clone that stimulated C3 CTLs encoding the spectrin-β2 R913L mutation. f, qRT-PCR for mutant spectrin-β2 in d42m1-related tumours and 1773. g, IFN-γ release by C3 CTLs incubated with COS-Db cells pulsed with WT (circles) or mutant (squares) spectrin-β2 peptides. Data are representative of three independent experiments. Samples were compared using an unpaired, two-tailed Student’s t test (*p<0.05, **p<0.01, and ***p<0.001; n.s. is non-significant).